Therapeutic agent for disc herniation
AssigneeSeikagaku Corporation
InventorsTaiichi Sirogane, Takao Murayama, Masafumi Yaguchi
Life of this patent
Estimating the term…
Abstract
The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.
Claims22
A method for treating lumbar disc herniation, comprising:
- injecting a formulation consisting essentially of chondroitinase ABC in an effective amount of 1-3 units per disc in a single dose into a disc of a human patient with disc herniation.
A method for treating lumbar disc herniation, comprising:
- injecting a formulation that comprises chondroitinase ABC in an effective amount of 1-3 units per disc in a single dose into a disc of a human patient with disc herniation,
- wherein chondroitinase ABC is a sole active ingredient for therapeutic effect in lumbar disc herniation of the formulation.
Dependencies are inferred from the claim text.